What is sandostatin lar?

What is Sandostatin LAR?

Sandostatin LAR is a long-acting injectable form of octreotide, a medication that mimics the natural hormone somatostatin. It comes as a powder that medics mix with diluent before intramuscular injection. It works by suppressing the release of several hormones and neurotransmitters, including growth hormone, insulin, glucagon, and serotonin.

How does Sandostatin LAR differ from regular Sandostatin?

Regular Sandostatin is a short-acting subcutaneous injection that must be given two or three times daily. Sandostatin LAR is designed for once-monthly administration. The long-acting microspheres gradually release octreotide over four weeks, so patients avoid daily shots and gain consistent hormone suppression.

When does Sandostatin LAR patent expire?

The original composition-of-matter patent covering the long-acting microsphere technology expired in the 1990s. Current exclusivity rests mainly on regulatory data protection and any secondary patents filed by Novartis. On DrugPatentWatch.com you can track remaining patent life and any Paragraph IV challenges.

Why are companies challenging this patent?

Generic manufacturers file Paragraph IV certifications when they believe older microsphere patents are invalid or not infringed. History shows similar claims for long-acting somatostatin analogs have sometimes led to litigation that delays generic entry.

What happens if a generic enters before patent expiry?

A successful Paragraph IV challenge could bring lower-cost octreotide LAR generics to market. Patients would gain access to competitive pricing, but any settlement or court win by Novartis could still delay arrival of cheaper versions.

Can biosimilars enter before patent expiry?

Sandostatin LAR is a small-molecule peptide packaged in polymer microspheres, not a biological. Therefore, standard generic ANDA pathways apply rather than biosimilar pathways.